Stifel Maintains Buy on Zymeworks, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Stephen Willey maintains a Buy rating on Zymeworks and raises the price target from $21 to $28.
October 28, 2024 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Stephen Willey has maintained a Buy rating on Zymeworks and increased the price target from $21 to $28, indicating a positive outlook for the stock.
The increase in price target from $21 to $28 by Stifel suggests a positive outlook for Zymeworks, likely leading to a short-term increase in stock price. The Buy rating further supports this positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100